Recognition of Non-Operating Income (Subsidy Income)
StemRIM Inc.
Development of a curative gene therapy technology for severe nutritional dystrophic epidermolysis bullosa; stem cell gene therapy (development code: SR-GT1)
The company was selected for a project conducted by AMED, and receipt of the FY2025 subsidy has been confirmed.
¥59.973 million (non-operating income; subsidy income)
The fourth-quarter accounting period of the fiscal year ending July 2026 (1 May 2026 to 31 July 2026)
Related procedures
Japan Agency for Medical Research and Development (AMED); Pharmaceuticals and Medical Devices Agency (PMDA)
The company aims to manufacture the investigational drug and promptly transition to an investigator-initiated clinical trial.
| Item | Details |
|---|---|
| Event name | Recognition of Non-Operating Income (Subsidy Income) |
| Subject Entity | StemRIM Inc. |
| Target Locations / Products | Development of a curative gene therapy technology for severe nutritional dystrophic epidermolysis bullosa; stem cell gene therapy (development code: SR-GT1) |
| Cause | The company was selected for a project conducted by AMED, and receipt of the FY2025 subsidy has been confirmed. |
| Amount of Impact on Business Performance | ¥59.973 million (non-operating income; subsidy income) |
| Accounting period in which recognized | The fourth-quarter accounting period of the fiscal year ending July 2026 (1 May 2026 to 31 July 2026) |
| Court or authority | Japan Agency for Medical Research and Development (AMED); Pharmaceuticals and Medical Devices Agency (PMDA) |
| Outlook | The company aims to manufacture the investigational drug and promptly transition to an investigator-initiated clinical trial. |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company was selected for a project conducted by AMED, and receipt of the FY2025 subsidy related to that project has been confirmed. The company explains that AMED will provide a subsidy covering two-thirds of the expenses incurred.